Related references
Note: Only part of the references are listed.The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single-Sequence Crossover Study
Samira Garonzik et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2019)
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy
Leonardo Di Gennaro et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers
Amichai Perlman et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants
S. Testa et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients
Bruria Hirsh Raccah et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2018)
Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects
Poe-Hirr Hsyu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation
Shang-Hung Chang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban
Teruhiro Sakaguchi et al.
JOURNAL OF CARDIOLOGY (2017)
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation A Review
John W. Eikelboom et al.
JAMA CARDIOLOGY (2017)
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
Charles Frost et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2017)
Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa
Blisse Vakkalagadda et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2016)
Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine
Dolly A. Parasrampuria et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers
Lori A. Gordon et al.
CIRCULATION (2016)
Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin
Barbara S. Wiggins et al.
PHARMACOTHERAPY (2016)
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Charles E. Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
Jeanne Mendell et al.
CLINICAL DRUG INVESTIGATION (2015)
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Christian T. Ruff et al.
LANCET (2015)
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
An Open-Label Study to Estimate the Effect of Steady-State Erythromycin on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban in Subjects with Renal Impairment and Normal Renal Function
Kenneth T. Moore et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
Paul A. Reilly et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
Jeanne Mendell et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2013)
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
Charles Frost et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy subjects
Sebastian Haertter et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
Wolfgang Mueck et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin
Xavier Delavenne et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban
Inna Y. Gong et al.
CANADIAN JOURNAL OF CARDIOLOGY (2013)
EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
Hein Heidbuchel et al.
EUROPEAN HEART JOURNAL (2013)
Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers
Sebastian Haertter et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor
Jeanne Mendell et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Vijay V. Upreti et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2013)
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects
Nobuko Matsushima et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban
Donglu Zhang et al.
DRUG METABOLISM AND DISPOSITION (2013)
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin
Sebastian Haertter et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, With Coadministration of Digoxin
Joachim Stangier et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects
D. Kubitza et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban
Kenneth Todd Moore et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial
K-H Liesenfeld et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Coadministration of Dabigatran Etexilate and Atorvastatin Assessment of Potential Impact on Pharmacokinetics and Pharmacodynamics
Joachim Stangier et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects
Joachim Stangier et al.
CLINICAL PHARMACOKINETICS (2008)
Cyclooxygenase Inhibitors Down Regulate P-glycoprotein in Human Colorectal Caco-2 Cell Line
Afraa Zrieki et al.
PHARMACEUTICAL RESEARCH (2008)
Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen
Dagmar Kubitza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients:: a population model analysis
Karl-Heinz Liesenfeld et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Valentin Fuster et al.
CIRCULATION (2006)
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (Rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects
D Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - Are not affected by aspirin
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
WE Evans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
In vivo modulation of CYP enzymes by quinidine and rifampin
RA Branch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
